Estrogen receptor

Assets acting on this target.

Class
small molecule
Notes
original target text: Estrogen receptor degrader

The estrogen receptor (ER) is a nuclear hormone receptor found inside cells, particularly in breast, uterine, and bone tissue. When the hormone estrogen binds to it, the receptor changes shape, moves into the nucleus, and attaches to DNA to switch on genes that drive cell growth and division. In a large share of breast cancers, this signaling pathway becomes a primary driver of tumor growth, making the receptor an attractive drug target. Selective estrogen receptor degraders (SERDs) are small molecules designed to bind the receptor and promote its breakdown by the cell's protein disposal machinery, reducing the total amount of receptor available regardless of estrogen levels. This differs from older strategies that simply block the hormone from binding or lower estrogen production throughout the body. By eliminating the receptor itself, degraders aim to shut down its activity more completely and to remain effective even when tumors develop mutations that make the receptor active without estrogen. This mechanism is broadly relevant to hormone receptor-positive breast cancer and is being explored in other estrogen-driven conditions.

By indication

Related mechanisms

Estrogen receptor drugs compared

9 drugs, stage by indication
9 drugs acting on Estrogen receptor: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
CamizestrantEtcamahAstraZenecasmall moleculeApprovedApproved in Breast Cancer; Approved in HR+/HER2- Metastatic Breast Cancer
ElacestrantA. Menarini, Radius Pharmaceuticals, Stemline Therapeutics, Inc.small moleculeApprovedApproved in Breast Cancer; Approved in HR+/HER2- Metastatic Breast Cancer
FulvestrantFaslodexAstraZenecasmall moleculeApprovedApproved in Breast Cancer; Approved in HR+/HER2- Metastatic Breast Cancer
ImlunestrantInluriyoEli Lillysmall moleculeApprovedApproved in Breast Cancer; Approved in HR+/HER2- Metastatic Breast Cancer
Tamoxifen (Soltamox)SoltamoxMayne Pharma, Rosemont Pharmaceuticalssmall moleculeApprovedApproved in Breast Cancer; Approved in HR+/HER2- Metastatic Breast Cancer
VepdegestrantVeppanuArvinas Inc., Pfizer, Rigel Pharmaceuticalssmall moleculeApprovedApproved in Breast Cancer; Approved in HR+/HER2- Metastatic Breast Cancer
GiredestrantRochesmall moleculePhase 3Phase 3 in HR+/HER2- Metastatic Breast Cancer
PalazestrantOlema Pharmaceuticals, Inc.small moleculePhase 3Phase 3 in HR+/HER2- Metastatic Breast Cancer
TaragarestrantInventisBiosmall moleculePhase 3Phase 3 in HR+/HER2- Metastatic Breast Cancer

← all mechanisms